Scott L. Burrows, Chief Financial Officer at Spyre Therapeutics, Inc. (SYRE), sold 15,000 shares at $87.12 ($1.3M) on 2026-06-25, disclosed to the SEC on 2026-06-26.
Open-market sale of $1.3M SYRE by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $87.12 | 5,000 | $436K | 33.3% |
| 2 | $87.14 | 10,000 | $871K | 66.7% |
| Total | $87.13 avg | 15,000 | $1.3M | 100% |
| Filing → |
| SYRE | SELL | 2026-08-05 | $717K | — | Filing → |
| SYRE | SELL | 2026-07-02 | $658K | — | Filing → |
| SYRE | SELL | 2026-06-03 | $533K | — | Filing → |